Evaluation of first trimester maternal serum inhibin-A for preeclampsia screening.

ABSTRACT:

Background

International professional organizations recommend aspirin prophylaxis to women screened high risk for preterm preeclampsia (PE) in the first trimester. The UK Fetal Medicine Foundation (FMF) screening test for preterm PE using mean arterial pressure (MAP), uterine artery pulsatility index (UTPI) and placental growth factor (PlGF) was demonstrated to have lower detection rate (DR) in Asian population studies. Additional biomarkers are therefore needed in Asian women to improve screening DRs as a significant proportion of women with preterm and term PE are currently not identified.

Objectives

To evaluate maternal serum inhibin-A at 11-13 weeks as an alternative to PlGF or as an additional biomarker within the FMF screening test for preterm PE.

Study design

T

SUBMITTER: Moungmaithong S 

PROVIDER: S-EPMC10332599 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature